Fig. 5: Genomic biomarker-linked therapies in patients with discordant results between non-CGP CDx and CGP.

a, Concordance rate between non-CGP CDx and CGP among patients positive by either or both tests for each genetic alteration and primary organ/tissue. (+) and (−) indicate positive and negative results, respectively. b, BOR to trastuzumab with or without pertuzumab in combination with hormone therapy and (or) chemotherapy in patients with breast cancer harboring ERBB2 amplification (determined by CGP), stratified by HER2 status determined by IHC/ISH assays. For patients treated with trastuzumab in multiple post-CGP regimens, only the earliest treatment with BOR data available was included. HER2-negative and HER2-low patients had no administration of trastuzumab and/or pertuzumab before CGP, whereas most HER2-positive patients had received these therapies before CGP. c, BOR to EGFR inhibitors in patients with lung cancer harboring EGFR mutations (determined by CGP), stratified by EGFR mutation status determined by non-CGP CDx. For patients treated with multiple EGFR inhibitors, the earliest treatment with BOR data available was included. Patients negative by non-CGP CDx had no administration of EGFR inhibitors before CGP, whereas most positive patients had received these therapies before CGP. a–c, Numbers in parentheses indicate the number of evaluated patients. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.